Monday, June 4, 2012

EULAR 2012 in Berlin – focussing

Tomorrow I’ll start for Berlin to the 2012 Meeting of EULAR. Concerning rheumatoid arthritis I have done my homework where to put the focus. Here are some ideas:

1. Biosimilars
How far have we come? What will be on the market as alternative to existing products?

2. Anti-CD-20 Monoclonal Antibody (like Rituximab)
Is ofatumumab still in the race?
How about ocrelizumab?
And veltuzumab?

3. Co-Stimulation-Inhibition
Subcutaneous abatacept, when will it be available?

4. Anti-Interleukin-6 Monoclonal Antibody (like Tocilizumab)
How far has BMS-945429 (ALD518), an anti-IL-6 monoclonal antibody, come? An alternative to tocilizumab?
And CDP6038, another anti-IL-6 monoclonal antibody?
Sarilumab, another anti-IL-6 monoclonal antibody, has already been in a phase 2 study last year, what’s new?
How about subcutaneous tocilizumab?

5. Anti-BAFF Monoclonal Antibody
Has LY2127399 (an anti-BAFF monoclonal antibody) been studied further?
Has atacicept [works on BLys(B-lymphocyte stimulator) and APRIL (A PRoliferation Inducing Ligand)] shown new efficacy?

6. Anti-Lymphotoxin-alpha Monoclonal Antibody
Is MLTA3698A, an anti-lymphotoxin-alpha monoclonal antibody, still studied?

7. Secukinumab (an Anti-Il17a Monoclonal Antibody)
Is secukinumab (AIN457), an anti-IL17A monoclonal antibody, still under study?

8. Oral JAK-Inhibitor, “small molecules”, SYK-Inhibitor and others
The oral jak inhibitor tofacitinib (CP-690,550) will most probably attract most attention. When will the drug be available?
GLPG0259, a MAPKAPK5 inhibitor, should be abandoned.
Has AMAP102, an orally available 5-HT2 receptor antagonist been studied further in a phase 2 study as planned?
Concerning fostamatinib (a SYK inhibitor), how far have we come during the past year?, pain, fatigue, and overall physical health status.
Do we have new data on the oral S1P lyase inhibitor LX3305 (LX2931)?

9. IL-1Ra-Receptor antagonist
New developments concerning anakinra?

10. Some further ideas after today's preliminary session (06.06.2012)
* SBI-087 is a SMIP (= small molecule immune pharmaceutical) binding to CD-20
* Sirukumab MAB against IL-6
* Mavrilimumab MAB against GM-CSF
* NKG2a - negative regulator of cell activation
* Cetrorelix - GnRH-antagonist
* CCX354-C and CCX168, which are chemokin-inhibitors
* Dekavil - fibronectin-A-chain connected to IL-10
* GLPG0634 - JAK1 inhibitor

No comments:

Post a Comment